Company Research Report: CSA Medical, Inc.

Company Overview

• Name of the Company: CSA Medical, Inc.

• Mission of the Company: Committed to developing spray cryotherapy devices that improve the lives of people suffering from COPD with Chronic Bronchitis. The company advances its core liquid nitrogen spray technology to target the underlying cause of Chronic Bronchitis – overproduction of mucus and damaged cilia within the airways.

• Founded: No information is available.

• Founders: No information is available.

• Key People in the Company: Wendelin Maners (Chief Executive Officer), Dr. Luc Marengere (Board Member from TVM Capital Life Science), Dr. Deng Mao (Board Member from Yonjin Ventures).

• Headquarters: 131 Hartwell Avenue, Lexington, Massachusetts 02421, USA.

• Number of Employees: No information is available.

• Revenue of the Company: No information is available.

• Known For: The RejuvenAir® System, a breakthrough medical device designed to treat the underlying cause of COPD with Chronic Bronchitis.

Products

RejuvenAir® System

• Product Description: RejuvenAir System is a revolutionary cryosurgical device that applies a precise thermal dose or “metered cryospray” of extremely cold, -196°C liquid nitrogen to targeted areas within the lungs. This is done through a minimally invasive, often outpatient or same-day bronchoscopic procedure aimed at treating the underlying cause of COPD with Chronic Bronchitis.

• Key Features:

• Utilizes a metered cryospray technology to flash freeze the surface area of damaged airways.

• Targets and destroys diseased cells without creating scar tissue.

• Enables rapid regrowth of new, healthy cells, including cilia and mucus-producing goblet cells.

• Designed specifically to reduce mucous production, cough, and inflammation in Chronic Bronchitis patients.

• Currently investigational and not commercially available in the United States.

Recent Developments

• Clinical Trials and Studies:

• The SPRAY-CB Clinical Trial is actively researching the effectiveness of the RejuvenAir System in improving the lives of patients with Chronic Bronchitis.

• First randomized controlled study demonstrated clinically significant results with Metered Cryospray for Chronic Bronchitis.

• New Products Launched: No new product launch information is available.

• New Features Added to Existing Products: No information on additional features added to existing products.

• Partnerships and Financial Developments:

• CSA Medical raised $53 million in Series D financing to support the PMA (Premarket Approval) of the RejuvenAir System. The financing was co-led by TVM Capital Life Science and Yonjin Ventures, with participation from existing investors including SV Health Investors, Ascension Ventures, First Analysis, Blue Heron, and Intersouth Partners.

• New board members from TVM Capital Life Science and Yonjin Ventures have joined to further support CSA Medical’s strategic initiatives.

• Scientific and Medical Developments:

• Recent data was presented at prestigious conferences, such as the American College of Chest Physicians and the European Respiratory Society Congress, which detailed the efficacy and clinical outcomes of the RejuvenAir® System for Chronic Bronchitis.

• Metered Cryospray showcased positive clinical outcomes indicating airway remodeling, potential mechanism of action in symptom reduction and lung repair, after treatment with RejuvenAir.

This report encapsulates the company's dedication to innovation in treating Chronic Bronchitis and highlights ongoing clinical research, financial growth strategies, and scientific advancements in their core product offerings.